Stem cell therapy for rare eye disease passes 5-year safety check

NCT ID NCT05786287

Not yet recruiting Disease control Sponsor: PT. Prodia Stem Cell Indonesia Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows up 18 people who received umbilical cord stem cells or conditioned medium for retinitis pigmentosa, a rare eye disease that causes vision loss. Researchers will check vision, eye structure, and safety five years after the injection. The goal is to see if the treatment remains safe over the long term.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: umbilical cord mesenchymal stem cells and conditioned medium
What this could lead to: If successful, this could show that stem cell therapy is safe for long-term use in retinitis pigmentosa, possibly slowing vision loss.
What could go wrong: This is a very small, early safety follow-up with only 18 people, not designed to prove the treatment works. Risks include injection-related complications and uncertain long-term benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RETINITIS PIGMENTOSA

Contacts and locations

Locations

Jakarta Eye Center Hospital

Jakarta, DKI Jakarta, Indonesia
Sardjito Hospital

Yogyakarta, Special Region, 55284, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.